eye103

Small moleculeexperimental

Clinical trial activity

4 trials · 1 clinical orgs · 0 marketing orgs

Phase 1
1
Phase 2
2
Phase 3
2
Phase 4
0

Earliest trial started Jun 12, 2023 (NCT05919693)

Timeline

2020s

  1. Jan 1, 2023

    Earliest Phase 1 Sponsor(trial)

  2. Jan 1, 2024

    Earliest Phase 2 Sponsor(trial)

Indications

Mechanism of action

Chemistry & pharmacology

Oral

No

Parenteral

No

Topical

No

Clinical trials

NCT IDPhaseStart dateSponsor(s)
NCT07205887Phase 2Sep 12, 2025EyeBiotech Ltd.
NCT06957080Phase 2/Phase 3 (Phase 3)Apr 16, 2025EyeBiotech Ltd.
NCT06571045Phase 2/Phase 3 (Phase 3)Aug 14, 2024EyeBiotech Ltd.
NCT05919693Phase 1/Phase 2 (Phase 2)Jun 12, 2023EyeBiotech Ltd.
Showing 4 of 4 trials
Page 1 / 1

Organizations

Research & Development (1)

OrganizationOrg typeTrialsAs lead sponsorPhasesEarliest year
EyeBiotech Ltd.For profit4422023
1 organizations
Page 1 / 1